Christopher Tyson

Christopher Tyson

Auto-generated profile, based on publicly available information

Christopher Tyson

Abbott (United States) 1 , Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
VGVladimir G. Gainullin
Vladimir G. Gainullin
MMMael Manesse
Mael Manesse
FZFanglei Zhuang
Fanglei Zhuang
MGMelissa Gray
Melissa Gray
HHHee Jung Hwang
Hee Jung Hwang
FDFrank Diehl
Frank Diehl
Background: Multibiomarker blood tests have the potential to detect a broad range of cancer types and stages. In this study, we assessed the performance of a methylation and protein (MP) classifier using samples from a large, multicenter, prospectively collected case–control study. As part of the assay development process, we performed an exploratory analysis investigating the addition of a somatic mutation reflex approach (MP-reflex) on samples with scores below the threshold for a positive MP call but above a clear negative MP call. Methods: This study included 6,352 (1,438 cancer and 4,914 noncancer) samples representing all stages among 21 tumor organ types divided approximately equally between a training set and a test set. The sensitivity of the MP classifier was determined at a high specificity. The MP-reflex approach was investigated on MP samples at the same specificity threshold and detectable MP signals above prespecified lower thresholds. Results: Overall sensitivities for MP biomarkers were 50.9% (98.5% specificity), with sensitivities of 15.4%, 26.1%, 38%, 67.8%, 85.5%, and 37.5% for stages I, I and II combined, II, III, IV, and unknown, respectively. With breast and prostate cancers excluded, overall test sensitivities were 56.8%, with sensitivities of 17.2%, 30.7%, 48.6%, 73.5%, 86.5%, and 40% for stages I, I and II combined, II, III, IV, and unknown, respectively. Conclusions: MP biomarkers detected all solid cancers analyzed, including those without recommended screening and aggressive cancers with poor 5-year survival. Impact: These results demonstrate the potential clinical validity of multibiomarker testing for the detection of several cancer types.

3 August 2026
Verified
Other
Open access
MYMenggang Yu
Menggang Yu
CTChristopher Tyson
Christopher Tyson
PLPaul J. Limburg
Paul J. Limburg
TBTomasz M. Beer
Tomasz M. Beer
Supplementary Materials and Methods shows the mathematic derivation

3 August 2026
Verified
Other
Open access
MYMenggang Yu
Menggang Yu
CTChristopher Tyson
Christopher Tyson
PLPaul J. Limburg
Paul J. Limburg
TBTomasz M. Beer
Tomasz M. Beer
Background:Earlier cancer detection through advancements in screening technologies and increased screening access and adherence may improve cancer survival. We developed a quantitative approach using a matrix equation to characterize cancer stage shift resulting from cancer screening interventions and estimated resulting survival improvements. Methods:The expected percent survival improvement was defined a priori as 20%, and the analysis sought to characterize the stage shift required to achieve this goal. The matrix equation was populated with incidence and cause-specific survival for 16 cancers by stage at diagnosis using the National Cancer Institute Surveillance, Epidemiology, and End Results database. Linear programming was used to solve for the matrix given a set of constraints formulated to steer the solution toward the least amount of downstaging required to achieve the objective and to partially compensate for length-time bias. Results:Three common trends emerged across almost all cancer types: (i) Most of the survival improvement can be achieved by detecting disease prior to stage IV; (ii) remaining survival improvements can be achieved by detecting just one stage earlier; and (iii) stage I diagnosis is not necessary to achieve measurable survival improvement goals. Lung cancer required more aggressive earlier detection than others, an expected result as lung cancer has a very high incidence and very poor survival. Conclusions:This flexible mathematical framework may be helpful for public health officials to characterize how earlier cancer detection can affect cancer survival. Impact:Our results suggest that detecting cancer prior to distant metastases may significantly improve survival.

1 October 2026 in Cancer Prevention Research
Verified
Journal Article
Open access
EFEliot Keith Fishman
Eliot Keith Fishman
JOJames M. O’BRien
James M. O’BRien
CTChristopher Tyson
Christopher Tyson
XCXiting Cao
Xiting Cao
KLKevin H. Li
Kevin H. Li
TBTomasz M. Beer
Tomasz M. Beer

24 June 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
MYMenggang Yu
Menggang Yu
CTChristopher Tyson
Christopher Tyson
PLPaul J. Limburg
Paul J. Limburg
TBTomasz M. Beer
Tomasz M. Beer
Background: Earlier cancer detection through advancements in screening technologies and increased screening access and adherence may improve cancer survival. We developed a quantitative approach using a matrix equation to characterize cancer stage shift resulting from cancer screening interventions and estimated resulting survival improvements. Methods: The expected percent survival improvement was defined a priori as 20%, and the analysis sought to characterize the stage shift required to achieve this goal. The matrix equation was populated with incidence and cause-specific survival for 16 cancers by stage at diagnosis using the National Cancer Institute Surveillance, Epidemiology, and End Results database. Linear programming was used to solve for the matrix given a set of constraints formulated to steer the solution toward the least amount of downstaging required to achieve the objective and to partially compensate for length-time bias. Results: Three common trends emerged across almost all cancer types: (i) Most of the survival improvement can be achieved by detecting disease prior to stage IV; (ii) remaining survival improvements can be achieved by detecting just one stage earlier; and (iii) stage I diagnosis is not necessary to achieve measurable survival improvement goals. Lung cancer required more aggressive earlier detection than others, an expected result as lung cancer has a very high incidence and very poor survival. Conclusions: This flexible mathematical framework may be helpful for public health officials to characterize how earlier cancer detection can affect cancer survival. Impact: Our results suggest that detecting cancer prior to distant metastases may significantly improve survival.